Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
AstraZeneca
Accenture
Argus Health
Harvard Business School
US Department of Justice
Chinese Patent Office
Johnson and Johnson
UBS

Generated: August 14, 2018

DrugPatentWatch Database Preview

Abraxis Bioscience Company Profile

« Back to Dashboard

Summary for Abraxis Bioscience
International Patents:266
US Patents:12
Tradenames:1
Ingredients:1
NDAs:1
Patent Litigation for Abraxis Bioscience: See patent lawsuits for Abraxis Bioscience

Drugs and US Patents for Abraxis Bioscience

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes 9,393,318 ➤ Sign Up ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes 8,314,156 ➤ Sign Up ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes 8,138,229 ➤ Sign Up Y ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes 9,101,543 ➤ Sign Up ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes 9,511,046 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Abraxis Bioscience

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 6,749,868 ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 5,439,686 ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 6,753,006 ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 6,096,331 ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RE41884 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ABRAXIS BIOSCIENCE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Injection Suspension 100 mg/vial ➤ Subscribe 2015-12-11

Non-Orange Book US Patents for Abraxis Bioscience

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,855,220 Methods of treating pancreatic cancer ➤ Sign Up
5,439,686 Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor ➤ Sign Up
9,012,518 Compositions and methods of delivery of pharmacological agents ➤ Sign Up
5,635,207 Methods for the preparation of blood substitutes for in vivo delivery ➤ Sign Up
5,650,156 Methods for in vivo delivery of nutriceuticals and compositions useful therefor ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Abraxis Bioscience Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
613 Luxembourg ➤ Sign Up 91613, EXPIRES: 20220924
2014 00034 Denmark ➤ Sign Up PRODUCT NAME: PACLITAXEL FORMULERET SOM ALBUMINBUNDNE NANOPARTIKLER; REG. NO/DATE: C(2013)9835 20131220
0961612/01 Switzerland ➤ Sign Up PRODUCT NAME: PACLITAXELUM-ALBUMINUM; REGISTRATION NO/DATE: SWISSMEDIC 63182 26.08.2014
2014022 Lithuania ➤ Sign Up PRODUCT NAME: PACLITAXELUM; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
1 Finland ➤ Sign Up
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Dow
UBS
Chinese Patent Office
McKesson
Teva
Johnson and Johnson
QuintilesIMS
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.